Spiegel et al. have performed comprehensive genomic profiling on lung cancer samples and reported that TMB was low in lung cancer harboring oncogenic driver mutations, but BRAF- (especially non-V600E) and KRAS-mutant patients were exceptional with a greater percentage of patients with high TMB. This evidence concerns the gene KRAS and lung carcinoma.